However, when the CD19 and CD22 dual‐target CAR‐T cells were utilized to treat B‐cell acute lymphoblastic leukemia, the tumor cells were still able to develop resistance to CAR‐T cell therapy by downregulating the expression of CD19 and CD22 antigens [16]. Here, CD22 is linked to neoplasm.